Northwest Biotherapeutics Announces $15 Million Financing
Northwest Biotherapeutics (NWBO) announced a successful closure of a $15 million financing on November 22, 2021, raising its cash reserves to over $20 million. The financing will support their brain cancer program, structured as a 22-month loan with an 8% annual interest rate.
Notably, this loan includes a provision allowing the lender to convert the outstanding balance into common shares following the announcement of top line data from a critical Phase III trial of DCVax®-L targeting Glioblastoma, potentially impacting future equity structure.
- Raised over $20 million in cash reserves.
- Funding will accelerate brain cancer program development.
- The loan carries a high annual interest rate of 8%.
- Lender's right to convert loan into shares could dilute existing shareholder equity.
BETHESDA, Md., Nov. 29, 2021 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced the closing of a
The Company plans to use the funding to help accelerate its activities related to its brain cancer program. The financing is in the form of a 22-month loan which requires no payments for 8 months, and then provides for a subsequent 14-month amortization period. The loan has a provision for prepayment, an annualized interest rate of
About Northwest Biotherapeutics
Northwest Biotherapeutics is a biotechnology company focused on developing personalized immunotherapy products designed to treat cancers more effectively than current treatments, without toxicities of the kind associated with chemotherapies, and on a cost-effective basis, in both North America and Europe. The Company has a broad platform technology for DCVax® dendritic cell-based vaccines. The Company's lead program is a 331-patient Phase III trial of DCVax®-L for newly diagnosed Glioblastoma multiforme (GBM). GBM is the most aggressive and lethal form of brain cancer, and is an "orphan disease." This Phase III trial reached data lock and the Company is actively continuing to move toward announcement of top line data. The Company has also developed DCVax®-Direct for inoperable solid tumor cancers. It has completed a 40-patient Phase I trial and, as resources permit, plans to pursue Phase II trials. The Company previously conducted a Phase I/II trial with DCVax-L for advanced ovarian cancer together with the University of Pennsylvania.
Disclaimer
Statements made in this news release that are not historical facts, including statements concerning future treatment of patients using DCVax and future clinical trials, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "expect," "believe," "intend," "design," "plan," "continue," "may," "will," "anticipate," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. We cannot guarantee that we actually will achieve the plans, intentions or expectations disclosed in our forward-looking statements and you should not place undue reliance on our forward-looking statements. Actual results may differ materially from those projected in any forward-looking statement. Specifically, there are a number of important factors that could cause actual results to differ materially from those anticipated, such as risks related to the Company's ability to achieve timely performance of third parties, risks related to whether the Company's products will demonstrate safety and efficacy, risks related to the Company's ongoing ability to raise additional capital, and other risks included in the Company's Securities and Exchange Commission ("SEC") filings. Additional information on the foregoing risk factors and other factors, including Risk Factors, which could affect the Company's results, is included in its SEC filings. Finally, there may be other factors not mentioned above or included in the Company's SEC filings that may cause actual results to differ materially from those projected in any forward-looking statement. The Company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by securities laws.
CONTACTS | |
Dave Innes | Les Goldman |
804-513-4758 dinnes@nwbio.com | 240-234-0059 lgoldman@nwbio.com |
View original content to download multimedia:https://www.prnewswire.com/news-releases/northwest-biotherapeutics-announces-15-million-financing-301432987.html
SOURCE Northwest Biotherapeutics
FAQ
What is the recent financing announcement by Northwest Biotherapeutics (NWBO)?
How will the $15 million financing affect Northwest Biotherapeutics (NWBO)?
What are the terms of the financing loan for NWBO?
What impact does the financing have on shareholders of Northwest Biotherapeutics (NWBO)?
When will Northwest Biotherapeutics (NWBO) announce top line data from their Phase III trial?
